These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12705416)

  • 1. Interest groups and state Medicaid drug programs.
    Pracht EE; Moore WJ
    J Health Polit Policy Law; 2003 Feb; 28(1):9-39. PubMed ID: 12705416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Access and cost implications of state limitations on Medicaid reimbursement for pharmaceuticals.
    Schweitzer SO; Shiota SR
    Annu Rev Public Health; 1992; 13():399-410. PubMed ID: 1599596
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2003.
    Johnson P
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-25. PubMed ID: 14969256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A critical analysis of studies of state drug reimbursement policies: research in need of discipline.
    Soumerai SB; Ross-Degnan D; Fortess EE; Abelson J
    Milbank Q; 1993; 71(2):217-52. PubMed ID: 8510601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicaid community-based programs: a longitudinal analysis of state variation in expenditures and utilization.
    Kitchener M; Carrillo H; Harrington C
    Inquiry; 2003; 40(4):375-89. PubMed ID: 15055836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bursting state fiscal bubble and state Medicaid budgets.
    Boyd DJ
    Health Aff (Millwood); 2003; 22(1):46-61. PubMed ID: 12528838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. States exempt psychiatric drugs in some Medicaid programs.
    Manag Care; 2003 Nov; 12(11):61. PubMed ID: 14666588
    [No Abstract]   [Full Text] [Related]  

  • 9. Decisions without consequences: cost control and access in state Medicaid programs.
    Barrilleaux CJ; Miller ME
    J Health Polit Policy Law; 1992; 17(1):97-118. PubMed ID: 1619253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State Medicaid pharmacy payments and their relation to estimated costs.
    Adams EK; Kreling DH; Gondek K
    Health Care Financ Rev; 1994; 15(3):25-42. PubMed ID: 10137796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Public preferences and organized interests in health policy: state pharmacy assistance programs as innovations.
    Gray V; Lowery D; Godwin EK
    J Health Polit Policy Law; 2007 Feb; 32(1):89-129. PubMed ID: 17312326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the potential impact of a prescription drug copayment increase on the adult asthmatic medicaid population.
    Bae SJ; Paltiel AD; Fuhlbrigge AL; Weiss ST; Kuntz KM
    Value Health; 2008; 11(1):110-8. PubMed ID: 18237365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicaid policies for HIV-related drug therapies: perspectives of the state affiliates of the American Pharmaceutical Association.
    Buchanan RJ; Smith SR
    Ann Pharmacother; 1994 Apr; 28(4):528-35. PubMed ID: 8038480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicaid policies for HIV-related prescription drugs.
    Buchanan RJ; Smith SR
    Health Care Financ Rev; 1994; 15(3):43-61. PubMed ID: 10137797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. States' control of prescription drug spending: a heterogeneous approach.
    Morden NE; Sullivan SD
    Health Aff (Millwood); 2005; 24(4):1032-8. PubMed ID: 16012143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug utilization and cost in a Medicaid population: a simulation study of community vs. mail order pharmacy.
    Valluri S; Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL
    BMC Health Serv Res; 2007 Jul; 7():122. PubMed ID: 17663768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. State model: Oregon. The ups and downs of Oregon's rationing plan.
    Fox DM; Leichter HM
    Health Aff (Millwood); 1993; 12(2):66-70. PubMed ID: 8375824
    [No Abstract]   [Full Text] [Related]  

  • 18. Varying health care provider objectives and cost-shifting: the case of retail pharmacy in the US.
    Brooks JM; Sorofman B; Doucette W
    Health Econ; 1999 Mar; 8(2):137-50. PubMed ID: 10342727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug companies crying foul over Medicaid's formulary push.
    Carroll J
    Manag Care; 2002 Nov; 11(11):12-4. PubMed ID: 12491852
    [No Abstract]   [Full Text] [Related]  

  • 20. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.